# Novavax Stock Surges 24% as Pfizer Deal and Earnings Beat Fuel Dramatic Turnaround

*2026-02-28 20:02 UTC · Business · 1 min read*

> Novavax shares hit 52-week high on massive earnings beat and $530M Pfizer licensing deal for Matrix-M adjuvant technology.

Novavax shares soared 24.4% to hit a new 52-week high after the biotech reported fourth-quarter 2025 revenue of $147 million, crushing Wall Street estimates of $90 million by 63%. The company swung to a net profit of $18 million from a loss of $81 million a year earlier, marking a pivotal shift in its financial trajectory.

The turnaround is powered by two major deals: a $225 million milestone from Sanofi and a $530 million non-exclusive licensing agreement with Pfizer for Novavax's Matrix-M adjuvant technology signed in January 2026. Pfizer will use the adjuvant across up to two disease areas, with $30 million upfront and up to $500 million in additional milestones. Novavax raised its 2026 adjusted revenue guidance to $230-270 million, up sharply from its prior $185-205 million forecast.

The stock is now up 56% year-to-date. Analysts see the Matrix-M platform as a game-changer that validates Novavax's pivot from a COVID-focused vaccine maker to a broader biotech licensing powerhouse.

## Sources

- [ir.novavax.com](https://ir.novavax.com/press-releases/2026-02-26-Novavax-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Operational-Highlights)
- [finance.yahoo.com](https://finance.yahoo.com/news/why-novavax-nvax-stock-soaring-180433998.html)
- [thedailyrecord.com](https://thedailyrecord.com/2026/02/26/novavax-raises-2026-revenue-forecast/)

---
TechTools News · https://techtools.cz/tools/news/article/481-novavax-stock-surges-24-as-pfizer-deal-and-earnings-beat-fuel-dramatic
Česká verze: https://techtools.cz/tools/news/clanek/482-akcie-novavaxu-vyskocily-o-24-diky-dohode-s-pfizerem-a-prekonani-ocekavani
